A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate

Vaccine

Volumn 33, Issue 30, 2015, Pages 3526-3532

  Zeng, Weiguang ^a   Tan, Amabel C L ^a   Horrocks, Kylie ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Extracellular domain; Influenza; Lipopeptide; M2 protein; Vaccine

Indexed keywords

CYSTEINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2B; INFLUENZA VACCINE; LIPOPEPTIDE; MATRIX PROTEIN 2 LIPOPEPTIDE; PEPTIDE VACCINE; PROTEIN M2; SERINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; IMMUNOGLOBULIN G; LIPID LINKED PROTEIN; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; S-(2,3-BIS(PALMITOYLOXY)PROPYL)CYSTEINE; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; DISEASE MODEL; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPID-LINKED PROTEINS; LIPOPEPTIDES; LUNG; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, SUBUNIT; VIRAL MATRIX PROTEINS;

EID: 84931576607     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.053     Document Type: Article

References (50)

1. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354:1277-1282.
2. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
3. Wong S-S., Webby R.J. Traditional and new influenza vaccines. Clin Microbiol Rev 2013, 26:476-492.
4. Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 2009, 87:300-308.
5. Epstein S.L., Price G.E. Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 2010, 9:1325-1341.
6. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A universal human influenza A vaccine. Virus Res 2004, 103:173-176.
7. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
8. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
9. Price G.E., Soboleski M.R., Lo C-Y., Misplon J.A., Quirion M.R., Houser K.V., et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 2010, 5:e13162.
10. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8:499-508.
11. Schotsaert M., Ysenbaert T., Neyt K., Ibanez L.I., Bogaert P., Schepens B., et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol 2013, 6:276-287.
12. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
13. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
14. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-1402.
15. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Lowenadler B., et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.
16. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283:11382-11387.
17. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londono-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507.
18. Turley C.B., Rupp R.E., Johnson C., Taylor D.N., Wolfson J., Tussey L., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4×M2e) in healthy adults. Vaccine 2011, 29:5145-5152.
19. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
20. Mozdzanowska K., Feng J., Eid M., Zharikova D., Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006, 352:418-426.
21. Mozdzanowska K., Feng J., Gerhard W. Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol 2003, 77:8322-8328.
22. Mozdzanowska K., Furchner M., Zharikova D., Feng J., Gerhard W. Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol 2005, 79:5943-5951.
23. Price G.E., Soboleski M.R., Lo C-Y., Misplon J.A., Pappas C., Houser K.V., et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512-6521.
24. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
25. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102.
26. Feng J.Q., Mozdzanowska K., Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 2002, 76:1369-1378.
27. Wolf A.I., Mozdzanowska K., Williams K.L., Singer D., Richter M., Hoffmann R., et al. Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS ONE 2011, 6:e28445.
28. Zhang M., Zharikova D., Mozdzanowska K., Otvos L., Gerhard W. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. Mol Immunol 2006, 43:2195-2206.
29. Zharikova D., Mozdzanowska K., Feng J., Zhang M., Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005, 79:6644-6654.
30. Pejoski D., Zeng W., Rockman S., Brown L.E., Jackson D.C. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol 2010, 88:605-611.
31. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25:8868-8873.
32. Zeng W., Ghosh S., Lau Y.F., Brown L.E., Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002, 169:4905-4912.
33. Zeng W., Horrocks K.J., Robevska G., Wong C.Y., Azzopardi K., Tauschek M., et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J Biol Chem 2011, 286:12944-12951.
34. Zeng W., Eriksson E., Chua B., Grollo L., Jackson D.C. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids 2010, 39:471-480.
35. Ng W.C., Gilbertson B., Lim B., Zeng W., Jackson D.C., Brown L.E. Lipopeptide vaccines illustrate the potential role of subtype-cross reactive T cells in the control of highly virulent influenza. Influenza Other Resp Viruses 2009, 3:177-182.
36. Wöhr T., Wahl F., Nefzi A., Rohwedder B., Sato T., Sun X., et al. Pseudo-prolines as a solubilizing, structure-disrupting protection technique in peptide synthesis. J Am Chem Soc 1996, 118:9218-9227.
37. Zeng W., Regamey P.O., Rose K., Wang Y., Bayer E. Use of Fmoc-N-(2-hydroxy-4-methoxybenzyl)amino acids in peptide synthesis. J Pept Res 1997, 49:273-279.
38. Kowalczyk W., de la Torre B.G., Andreu D. Strategies and limitations in dendrimeric immunogen synthesis. The influenza virus M2e epitope as a case study. Bioconjug Chem 2010, 21:102-110.
39. Takeda K., Takeuchi O., Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 2002, 8:459-463.
40. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
41. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
42. Batzloff M.R., Hartas J., Zeng W., Jackson D.C., Good M.F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006, 194:325-330.
43. Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 2010, 28:6393-6397.
44. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003, 21:3212-3218.
45. Lambrecht B., Steensels M., Van Borm S., Meulemans G., van den Berg T. Development of an M2e-specific enzyme-linked immunosorbent assay for differentiating infected from vaccinated animals. Avian Dis 2007, 51:221-226.
46. De Filette M., Ramne A., Birkett A., Lycke N., Lowenadler B., Min Jou W., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24:544-551.
47. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161.
48. Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008, 1:11-22.
49. Denkers E.Y., Badger C.C., Ledbetter J.A., Bernstein I.D. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol (Baltimore, Md: 1950) 1985, 135:2183-2186.
50. Kitikoon P., Strait E.L., Thacker E.L. The antibody responses to swine influenza virus (SIV) recombinant matrix 1 (rM1), matrix 2 (M2), and hemagglutinin (HA) proteins in pigs with different SIV exposure. Vet Microbiol 2008, 126:51-62.